Convergence of personalized healthcare and digital pathology

Get ready. The next digital frontier, diagnostics tests that intimately tie together the diagnostic imaging of pathology to the therapeutics of drug treatments, are moving personalized medicine, or personalized healthcare (PHC) closer to reality.

It's commonly accepted that a broad-brush approach in treating diseases doesn't always work. And if there's a disease ripe for PHC, it's cancer. The objective in personalized healthcare for cancer is to identify the right patients with the right molecular change, and then hit that patient's specific molecular change with the right drug. Several upcoming cancer tests will help usher in a renaissance in diagnostics.

How diagnostic tests will look in the future by Drs. Monroe and Walk

Dr. Robert Monroe, Chief Medical Officer at BioImagene, Inc., acquired by Ventana Medical Systems Inc., is a board certified pathologist with over 10 years of experience in anatomic pathology, cytopathology, and biomedical research, who leads the company's clinical studies on companion algorithms and digital pathology applications.

Dr. Eric Walk, Senior Vice President and Chief Medical Officer at Ventana Medical Systems, Inc., a member of the Roche Group, is a molecular and translational pathologist with over 10 years of experience in clinical diagnostic pathology, oncology drug development, oncology translational medicine/biomarker development and diagnostics.